AdociaLTS:0QAI +5.49%33 Gross Margin % is 9.23% as of Dec. 2025, which is 88% below its 10-year median of 74.18. GuruFocus rates LTS:0QAI with a GF Score™ of 33/100 and a GF Value™ of €0.90 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 736 Biotechnology companies, Adocia ranks worse than 62.91% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Adocia's Gross Profit for the
six
months ended in Dec. 2025 was €0.04 Mil. Adocia's Revenue for the
six
months ended in Dec. 2025 was €0.44 Mil. Therefore, Adocia's Gross Margin % for the quarter that ended in Dec. 2025 was 9.23%.
The historical rank and industry rank for Adocia's Gross Margin % or its related term are showing as below:
LTS:0QAI'
s Gross Margin % Range Over the Past 10 Years
Min: -73.25 Med: 74.18 Max: 95.38
Current: 46.31
During the past 13 years, the highestGross Margin % of Adocia was 95.38%. The lowest was -73.25%. And the median was 74.18%.
LTS:0QAI's Gross Margin % is ranked worse than 62.91% of 736
companies
in the Biotechnology industry
Industry Median: 60.91
vs LTS:0QAI: 46.31
Adocia had a gross margin of 9.23% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Adocia was 0.00% per year.
Adocia (LTS:0QAI) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Adocia had a gross margin of 9.23% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Adocia Gross Margin % Related Terms
Adocia Gross Margin % Historical Data
* Premium members only.
The historical data trend for Adocia's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QAI vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Adocia's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adocia Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adocia's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Adocia's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Adocia (LTS:0QAI) has a Gross Margin % of 9.23% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Adocia and its competitors. This is 88% below median its historical median of 74.18. According to the industry distribution chart, Adocia ranks #463 out of 736 companies in the Biotechnology industry, placing it in the top 62.9%.
Is Adocia's Gross Margin % too high?
Adocia's current Gross Margin % of 9.23% is 88% below median its 10-year median of 74.18. The Biotechnology industry median Gross Margin % is 60.91. Adocia's value of 9.23% is 84.8% below this industry median. Based on the distribution chart, Adocia ranks #463 out of 736 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Adocia has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adocia's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Adocia ranks #463 out of 736 companies for Gross Margin %. This places Adocia in the lower half of its industry. The industry median Gross Margin % is 60.91. Adocia's value of 9.23% is 84.8% below this benchmark. While the company's 10-year median is 74.18 vs. the industry median of 60.91, Adocia has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adocia's current Gross Margin % of 9.23% is 84.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Adocia and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adocia's current Gross Margin % is 9.23%, which is 88% below median its own 10-year median of 74.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adocia stock overvalued right now?
Based on GuruFocus' analysis, Adocia (LTS:0QAI) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.90, compared to a current price of €4.19 — trading 365.8% above its estimated fair value. The current Gross Margin % is 9.23%, which is 88% below median its 10-year median of 74.18 and 84.8% below the Biotechnology industry median of 60.91. Adocia's overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Adocia (LTS:0QAI), the current Gross Margin % is 9.23% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adocia (LTS:0QAI) Overvalued in 2026?
Based on GuruFocus' analysis, Adocia stock appears to be overvalued.
The current stock price of €4.19 is trading 365.8% above its estimated GF Value™ of €0.90.
GuruFocus considers Adocia to be Significantly Overvalued.
Key valuation signals for LTS:0QAI:
Gross Margin %: 9.23% (88% below median its 10-year median of 74.18)
GF Value™: €0.90 vs. price of €4.19 (365.8% above fair value)
Industry Position: 84.8% below the Biotechnology median (#463 of 736)
No single metric tells the full story. See the LTS:0QAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
33GF Score
Get the complete analysis for LTS:0QAI
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QAI has been successfully added to your 
